ReviewFrontiers in public health2026
Sexual dysfunction in chronic hepatitis B: a comprehensive review of pathophysiology, clinical burden, and integrated management.
Review in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis B (CHB) affects approximately 240 million people worldwide. Advances in antiviral therapy have shifted CHB management toward long-term, multidimensional care, in which sexual health is closely linked to psychological wellbeing, intimate relationships, and patient-clinician communication. However, sexual dysfunction (SD) in CHB remains insufficiently characterized and is not yet routinely integrated into clinical management. This narrative review synthesizes evidence focused on CHB regarding the epidemiology, clinical burden, pathophysiological mechanisms, and antiviral treatment implications of SD across disease stages and treatment contexts. Reported prevalence estimates vary widely, ranging from 8.6 to 63.1% across heterogeneous HBV-related studies. Mechanistically, SD in CHB appears to reflect interactions among biological vulnerability, psychological stressors, and lifestyle determinants. Evidence on treatment effects remains limited, but available data do not indicate a consistent adverse effect of nucleos(t)ide analogues on sexual function, whereas interferon-based regimens may indirectly contribute to SD through fatigue and neuropsychiatric symptoms. Accordingly, we propose an integrated management framework comprising proactive screening, multidimensional assessment, individualized intervention, and longitudinal monitoring. In practice, this framework emphasizes validated sexual function instruments, concurrent assessment of psychological distress, transmission concerns, closer monitoring of patients at higher risk, targeted symptom management, and coordinated multidisciplinary support when needed. Future research should prioritize prospective longitudinal studies, sex-specific analyses, standardized sexual function instruments, and inclusion of sexual health as a patient-reported endpoint in antiviral therapy trials to better define the burden, mechanisms, and management of SD in CHB.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.